exome sequencing
GeneDx Q2 Revenues Increase 35 Percent, Boosted by Growth in Exome, Genome Tests
The genetic testing firm is using AI to improve genome interpretation and help customers raise low reimbursement rates for whole-exome testing.
GeneDx Q1 Revenues Fall 20 Percent but Beat Consensus Estimate
Molecular diagnostic testing volume grew across all continuing operations in Q1 as GeneDx completed the shutdown of underperforming Sema4 assets.
UnitedHealthcare to Cover Whole-Genome Sequencing for Certain Non-Cancer Indications
The private payor published new coverage criteria for whole-genome sequencing tests for patients with a variety of non-cancer indications.
Rebranded GeneDx Bets Future on Whole-Exome, Whole-Genome Sequencing in Pediatric Rare Disease
Premium
After dropping underdeveloped Sema4 business lines but emphasizing the Centrellis informatics platform, the new GeneDx expects to reach profitability by 2025.
CEO and Cofounder İbrahim Çağrı Kurt discussed the new test during a presentation at Slush, an annual startup conference held in Helsinki this week.